Federal Register of Legislation - Australian Government

Primary content

PB 118 of 2010 Arrangements as amended, taking into account amendments up to National Health (Paraplegic and Quadriplegic Program) Special Arrangement Amendment Instrument 2020 (No. 1) (PB 7 of 2020)
Administered by: Health
Registered 06 Feb 2020
Start Date 01 Feb 2020

Commonwealth Coat of Arms of Australia

National Health (Paraplegic and Quadriplegic Program) Special Arrangement 2010 (PB 118 of 2010)

made under subsection 100(1) of the

National Health Act 1953

Compilation No. 18

Compilation date:                              1 February 2020

Includes amendments up to:            PB 7 of 2020

Registered:                                         6 February 2020

 

About this compilation

This compilation

This is a compilation of the National Health (Paraplegic and Quadriplegic Program) Special Arrangement 2010 (PB 118 of 2010) that shows the text of the law as amended and in force on 1 February 2020 (the compilation date).

The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled law.

Uncommenced amendments

The effect of uncommenced amendments is not shown in the text of the compiled law. Any uncommenced amendments affecting the law are accessible on the Legislation Register (www.legislation.gov.au). The details of amendments made up to, but not commenced at, the compilation date are underlined in the endnotes. For more information on any uncommenced amendments, see the series page on the Legislation Register for the compiled law.

Application, saving and transitional provisions for provisions and amendments

If the operation of a provision or amendment of the compiled law is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

Editorial changes

For more information about any editorial changes made in this compilation, see the endnotes.

Modifications

If the compiled law is modified by another law, the compiled law operates as modified but the modification does not amend the text of the law. Accordingly, this compilation does not show the text of the compiled law as modified. For more information on any modifications, see the series page on the Legislation Register for the compiled law.

Self-repealing provisions

If a provision of the compiled law has been repealed in accordance with a provision of the law, details are included in the endnotes.

  

  

  


Contents

Part 1—Preliminary                                                                                                                                        1

1............ Name of Special Arrangement....................................................................................... 1

3............ Definitions..................................................................................................................... 1

4............ Pharmaceutical benefits covered by this Special Arrangement...................................... 1

5............ Application of Part VII of the Act................................................................................. 2

6............ Responsible person....................................................................................................... 2

7............ No prescriber or prescription......................................................................................... 2

Part 2—Supply for the paraplegic and quadriplegic program                                            4

9............ Paraplegic and quadriplegic associations....................................................................... 4

10.......... Eligible persons............................................................................................................. 4

11.......... Maximum amount......................................................................................................... 4

12.......... Supply........................................................................................................................... 4

13.......... Co‑payment etc not to be made...................................................................................... 5

14.......... Payment from Commonwealth...................................................................................... 5

15.......... Charge for delivery........................................................................................................ 6

16.......... Claims for payment....................................................................................................... 6

17.......... Stock of pharmaceutical benefits etc.............................................................................. 6

Schedule 1—Pharmaceutical benefits covered by this Special Arrangement and related information                                                                                                                    7

Schedule 2—Responsible Person Codes                                                                            9

Endnotes                                                                                                                                                               10

Endnote 1—About the endnotes                                                                                                      10

Endnote 2—Abbreviation key                                                                                                          11

Endnote 3—Legislation history                                                                                                       12

Endnote 4—Amendment history                                                                                                     13

 


Part 1Preliminary

  

1  Name of Special Arrangement

             (1)  This Special Arrangement is the National Health (Paraplegic and Quadriplegic Program) Special Arrangement 2010.

             (2)  This Special Arrangement may also be cited as PB 118 of 2010.

3  Definitions

                   In this Special Arrangement:

ABN has the same meaning as in the A New Tax System (Australian Business Number) Act 1999.

Act means the National Health Act 1953.

authorised association means a paraplegic and quadriplegic association authorised to supply pharmaceutical benefits under this Special Arrangement by section 9.

eligible person means a person that is eligible to receive pharmaceutical benefits under section 10.

other Special Arrangement means another Special Arrangement under section 100 of the Act.

Note:          Terms used in this Special Arrangement have the same meaning as in the Act—see section 13 of the Legislative Instruments Act 2003. These terms include:

·         approved ex‑manufacturer price

·         brand

·         claimed price

·         listed drug

·         pack quantity

·         pharmaceutical benefit

·         pharmaceutical item

·         proportional ex‑manufacturer price

·         responsible person.

4  Pharmaceutical benefits covered by this Special Arrangement

             (1)  This Special Arrangement applies to each pharmaceutical benefit mentioned in Schedule 1.

             (2)  Each pharmaceutical benefit to which this Special Arrangement applies is a brand of a listed drug mentioned in Schedule 1:

                     (a)  in the form mentioned in Schedule 1 for the listed drug; and

                     (b)  with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

Note:          Each listed drug mentioned in Schedule 1 has been declared by the Minister under subsection 85(2) of the Act. The form, manner of administration and brand mentioned in Schedule 1 have been determined by the Minister under subsections 85(3), (5) and (6) of the Act respectively.

5  Application of Part VII of the Act

             (1)  Each pharmaceutical benefit supplied in accordance with this Special Arrangement is supplied under Part VII of the Act.

             (2)  A provision of Part VII of the Act, or of regulations or other instruments made for Part VII of the Act, applies subject to this Special Arrangement.

Note:          See subsection 100(3) of the Act.

6  Responsible person

             (1)  If a code is mentioned in the column in Schedule 1 headed ‘Responsible Person’ for a brand of a pharmaceutical item, the person mentioned in paragraph (2)(a) is the responsible person for the brand of the pharmaceutical item.

             (2)  For subsection (1):

                     (a)  the person is the person mentioned in Schedule 2 for the code, with the ABN, if any, mentioned in Schedule 2 for the person; and

                     (b)  the pharmaceutical item is the listed drug mentioned in Schedule 1:

                              (i)  in the form mentioned in Schedule 1 for the listed drug; and

                             (ii)  with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

Note:          A person identified by a code in the column headed ‘Responsible Person’ in Schedule 1 has been determined by the Minister, under section 84AF of the Act, to be the responsible person for the brand of the pharmaceutical item.

7  No prescriber or prescription

             (1)  Subsection 88(1) of the Act (authorising medical practitioners to prescribe pharmaceutical benefits) does not apply to the supply of a pharmaceutical benefit under this Special Arrangement.

             (2)  If a pharmaceutical benefit is supplied in accordance with this Special Arrangement, the following determinations do not apply to the supply:

                     (a)  a determination made under section 88 of the Act about authorised prescribers for the pharmaceutical benefit;

                     (b)  a determination made under paragraph 85(7)(b) of the Act about the circumstances in which a prescription for the pharmaceutical benefit may be written;

                     (c)  a determination made under paragraph 85A(2(a) of the Act about the maximum quantities or number of units of the pharmaceutical item in the pharmaceutical benefit that may, in 1 prescription, be directed to be supplied on any 1 occasion;

                     (d)  a determination made under paragraph 85A(2)(b) of the Act about the maximum number of occasions on which the pharmaceutical benefit may be directed to be supplied in a prescription.

Part 2Supply for the paraplegic and quadriplegic program

  

9  Paraplegic and quadriplegic associations

                   The following paraplegic and quadriplegic associations are authorised to supply pharmaceutical benefits under this Special Arrangement:

                     (a)  The Paraplegic & Quadriplegic Association of N S W (ABN 42 000 355 948);

                     (b)  Spinal Injuries Association Inc (ABN 39 293 063 049);

                     (c)  Paraquad Victoria (ABN 80 973 805 243).

10  Eligible persons

                   A person is eligible to receive a pharmaceutical benefit from an authorised association if the person:

                     (a)  is an eligible person within the meaning of the Health Insurance Act 1973; and

                     (b)  has paraplegia or quadriplegia; and

                     (c)  is a member of the association.

11  Maximum amount

             (1)  The maximum amount of the pharmaceutical item in a pharmaceutical benefit that may, during a month, be supplied by an authorised association to an eligible person is the amount mentioned in the column in Schedule 1 headed ‘Maximum Amount’ for the pharmaceutical benefit.

             (2)  For subsection (1):

                     (a)  the pharmaceutical item is the listed drug mentioned in Schedule 1:

                              (i)  in the form mentioned in Schedule 1 for the listed drug; and

                             (ii)  with the manner of administration mentioned in Schedule 1 for the form of the listed drug; and

                     (b)  the pharmaceutical benefit is the brand of the listed drug mentioned in Schedule 1:

                              (i)  in the form mentioned in Schedule 1 for the listed drug; and

                             (ii)  with the manner of administration mentioned in Schedule 1 for the form of the listed drug.

12  Supply

             (1)  An authorised association may supply a pharmaceutical benefit to an eligible person:

                     (a)  on the person’s request; and

                     (b)  despite section 89 of the Act, without a prescription written for the supply to the person.

Note:          Section 89 of the Act provides for pharmaceutical benefits to be supplied only on prescription.

             (2)  The association may supply the pharmaceutical benefit to the person by:

                     (a)  making the pharmaceutical benefit available to be picked up by the person at the association’s premises; or

                     (b)  sending the pharmaceutical benefit to the person.

13  Co‑payment etc not to be made

                   An authorised association must not demand or receive a payment or other valuable consideration for the supply of a pharmaceutical benefit under this Special Arrangement, other than:

                     (a)  a payment from the Commonwealth under section 14.

                     (b)  a charge mentioned in section 15.

14  Payment from Commonwealth

             (1)  An authorised association that supplies a pack quantity of a pharmaceutical benefit is entitled to be paid by the Commonwealth for the supply the amount worked out under subsection (2).

             (2)  For subsection (1), the amount is:

                     (a)  if there is no claimed price for the pack quantity of the pharmaceutical benefit:

                              (i)  the price to pharmacists for the pack quantity worked out under the determination under paragraph 98B(1)(a) of the Act; and

                             (ii)  a handling fee of 2.75% of that amount; or

                     (b)  if there is a claimed price for the pack quantity of the pharmaceutical benefit:

                              (i)  the claimed price for the pack quantity  plus a wholesale mark‑up calculated in accordance with subsection (3); and

                             (ii)  a handling fee of 2.75% of that amount.

             (3)  For paragraph (2)(b), the wholesale mark‑up for the pack quantity of the pharmaceutical benefit is to be worked out using the methodology for calculating the wholesale mark‑up for ready‑prepared pharmaceutical benefits in the determination under paragraph 98B(1)(a) of the Act, subject to the following:

                     (a)  for the purposes of identifying the appropriate wholesale mark‑up formula in Step 2 of the methodology, the ex‑manufacturer price for the relevant quantity is to be worked out proportionately from the approved ex‑manufacturer price or proportional ex‑manufacturer price for the pack quantity of the pharmaceutical benefit; and

                     (b)  otherwise, the methodology is to be applied as if the claimed price for the pack quantity of the pharmaceutical benefit were the approved ex‑manufacturer price or proportional ex‑manufacturer price for the pack quantity.

15  Charge for delivery

                   If an authorised association supplies a pharmaceutical benefit by sending it to a person the association may charge the person an amount that is equal to the cost of sending the pharmaceutical benefit to the person.

16  Claims for payment

             (1)  An authorised association that wants to receive payment for the supply of a pharmaceutical benefit under this Special Arrangement must make a claim for payment to the Medicare Australia CEO.

             (2)  Despite section 99AAA of the Act, the association must submit its claims for the supplies it makes during a month on a form approved in writing by the Medicare Australia CEO for this section.

Note:          Section 99AAA of the Act provides for rules to be made by the Minister about procedures for claims for payment.

17  Stock of pharmaceutical benefits etc

                   An authorised association may:

                     (a)  order a pharmaceutical benefit from:

                              (i)  the responsible person for the brand of the pharmaceutical item in the pharmaceutical benefit; or

                             (ii)  a wholesaler for the pharmaceutical benefit; and

                     (b)  keep in stock at its premises an adequate supply of pharmaceutical benefits for supply to its members under this Special Arrangement.


Schedule 1Pharmaceutical benefits covered by this Special Arrangement and related information

(sections 4, 6 and 11)

  

 

Listed Drug

Form

Manner of Administration

Brand

Responsible Person

Maximum Amount

Bisacodyl

Tablet, 5mg

oral

Lax‑Tab

AE

400

 

Suppositories 10mg, 10

rectal

Dulcolax

VZ

9

 

 

 

Petrus Bisacodyl Suppositories

PP

9

 

Suppositories 10mg, 12

rectal

Petrus Bisacodyl Suppositories

PP

8

 

Enemas 10mg in 5mL, 25

rectal

Bisalax

AS

2

Macrogol 3350

Sachets containing powder for oral solution 13.125g with electrolytes, 30

oral

APOHEALTH Macrogol with Electrolytes

GX

2

 

 

 

APO-MACROGOL plus ELECTROLYTES

TX

2

 

 

 

Chemists’ Own Macrogol with Electrolytes

RW

2

 

 

 

LaxaCon

EA

2

 

 

 

lax-sachets

AE

2

 

 

 

Macrovic

RF

2

 

 

 

Molaxole

GO

2

 

 

 

Movicol

NE

2

 

Powder for oral solution 510g

Oral

OsmoLax

KY

1

Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate

Enemas 3.125g‑450mg‑45mg in 5mL, 12

rectal

Micolette

AE

4

Sterculia with Frangula Bark

Granules 620mg‑80mg, per g, 500g

oral

Normacol Plus

NE

2

 


Schedule 2Responsible Person Codes

(section 6)

  

 

Code

Responsible Person

Australian Business Number

AE

AFT Pharmaceuticals (AU) Pty Ltd

29 105 636 413

AS

Aspen Pharmacare Australia Pty Limited

51 096 236 985

EA

Amneal Pharmaceuticals Pty Ltd

11 163 167 851

GO

Mylan Health Pty Ltd

29 601 608 771

GX

Apotex Pty Ltd

52 096 916 148

KY

Key Pharmaceuticals Pty Ltd

21 001 215 130

NE

Norgine Pty Ltd

78 005 022 882

PP

Petrus Pharmaceuticals Pty Ltd

21 108 884 126

RF

Arrow Pharma Pty Ltd

35 605 909 920

RW

Arrow Pharma Pty Ltd

35 605 909 920

TX

Apotex Pty Ltd

52 096 916 148

VZ

Sanofi-aventis Healthcare Pty Ltd

43 076 651 959

 


Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

Abbreviation key—Endnote 2

The abbreviation key sets out abbreviations that may be used in the endnotes.

Legislation history and amendment history—Endnotes 3 and 4

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

Editorial changes

The Legislation Act 2003 authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

Misdescribed amendments

A misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.

If a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history.

 

Endnote 2—Abbreviation key

 

ad = added or inserted

o = order(s)

am = amended

Ord = Ordinance

amdt = amendment

orig = original

c = clause(s)

par = paragraph(s)/subparagraph(s)

C[x] = Compilation No. x

    /sub‑subparagraph(s)

Ch = Chapter(s)

pres = present

def = definition(s)

prev = previous

Dict = Dictionary

(prev…) = previously

disallowed = disallowed by Parliament

Pt = Part(s)

Div = Division(s)

r = regulation(s)/rule(s)

ed = editorial change

reloc = relocated

exp = expires/expired or ceases/ceased to have

renum = renumbered

    effect

rep = repealed

F = Federal Register of Legislation

rs = repealed and substituted

gaz = gazette

s = section(s)/subsection(s)

LA = Legislation Act 2003

Sch = Schedule(s)

LIA = Legislative Instruments Act 2003

Sdiv = Subdivision(s)

(md) = misdescribed amendment can be given

SLI = Select Legislative Instrument

    effect

SR = Statutory Rules

(md not incorp) = misdescribed amendment

Sub‑Ch = Sub‑Chapter(s)

    cannot be given effect

SubPt = Subpart(s)

mod = modified/modification

underlining = whole or part not

No. = Number(s)

    commenced or to be commenced

 

Endnote 3—Legislation history

 

Name

Registration

Commencement

Application, saving and transitional provisions

PB 118 of 2010

29 Nov 2010 (F2010L03133)

1 Dec 2010 (s 2)

 

PB 42 of 2012

30 May 2012 (F2012L01116)

1 Apr 2012 (s 2)

PB 91 of 2012

28 Sept 2012 (F2012L01974)

1 Oct 2012 (s 2)

PB 51 of 2013

31 July 2013 (F2013L01481)

1 Aug 2013 (s 2)

PB 66 of 2013

24 Sept 2013 (F2013L01738)

1 Oct 2013 (s 2)

PB 87 of 2013

18 Nov 2013 (F2013L01947)

1 Dec 2013 (s 2)

PB 94 of 2013

24 Dec 2013 (F2013L02193)

1 Jan 2014 (s 2)

PB 35 of 2014

17 Apr 2014 (F2014L00427)

1 May 2014 (s 2)

PB 79 of 2014

26 Sept 2014 (F2014L01287)

1 Oct 2014 (s 2)

PB 62 of 2015

1 July 2015 (F2015L01068)

1 July 2015 (s 2)

PB 97 of 2015

1 Oct 2015 (F2015L01602)

1 Oct 2015 (s 2)

PB 116 of 2015

1 Dec 2015 (F2015L01893)

1 Dec 2015 (s 2)

PB 15 of 2016

1 Mar 2016 (F2016L00216)

1 Mar 2016 (s 2)

PB 35 of 2016

2 May 2016 (F2016L00622)

1 May 2016 (s 2)

PB 102 of 2016

13 Dec 2016 (F2016L01930)

1 Dec 2016 (s 2)

PB 7 of 2017

27 Jan 2017 (F2017L00075)

1 Feb 2017 (s 2)

PB 43 of 2017

31 May 2017 (F2017L00633)

1 June 2017 (s 2)

PB 28 of 2018

29 Mar 2018 (F2018L00454)

1 Apr 2018 (s 2)

PB 80 of 2018

31 Aug 2018 (F2018L01239)

1 Sept 2018 (s 2)

PB 7 of 2020

30 Jan 2020 (F2020L00066)

1 Feb 2020 (s 2)

 

Endnote 4—Amendment history

 

Provision affected

How affected

Part 1

 

s 2........................................

rep LA s 48D

s 3........................................

am PB 91 of 2012

s 8........................................

rep PB 91 of 2012

Part 2

 

s 14......................................

am PB 42 and 91 of 2012

Schedule 1

 

Schedule 1...........................

rs PB 91 of 2012

 

am PB 51, 66, 87 and 94 of 2013; PB 35 and 79 of 2014; PB 62 of 2015; PB 97 of 2015; PB 116 of 2015 (Sch 1 item 1 md not incorp); PB 15 of 2016; PB 35 of 2016; PB 102 of 2016

 

ed C13

 

am PB 7 of 2017; PB 43 of 2017; PB 28 of 2018; PB 80 of 2018; PB 7 of 2020

Schedule 2

 

Schedule 2...........................

am PB 51 and 66 of 2013; PB 79 of 2014; PB 62 of 2015; PB 97 of 2015; PB 15 of 2016; PB 7 of 2017; PB 43 of 2017

 

ed C15

 

am PB 28 of 2018; PB 7 of 2020